Daily Stock Analysis, ASNS, ASCENDIS PHARMA A/S - ADR, priceseries

ASCENDIS PHARMA A/S - ADR. Daily Stock Analysis
Stock Information
Open
2.60
Close
2.69
High
2.71
Low
2.60
Previous Close
2.56
Daily Price Gain
0.13
YTD High
3.93
YTD High Date
Jan 10, 2019
YTD Low
2.05
YTD Low Date
Feb 13, 2019
YTD Price Change
0.13
YTD Gain
5.08%
52 Week High
28.69
52 Week High Date
Mar 15, 2018
52 Week Low
1.15
52 Week Low Date
Nov 14, 2018
52 Week Price Change
-11.80
52 Week Gain
-81.44%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 27. 2018
17.41
May 15. 2018
18.82
12 Trading Days
8.09%
Link
LONG
Oct 3. 2018
1.68
Oct 10. 2018
1.78
5 Trading Days
5.80%
Link
LONG
Nov 8. 2018
1.43
Nov 9. 2018
1.53
1 Trading Days
6.99%
Link
LONG
Nov 29. 2018
3.71
Dec 3. 2018
4.04
2 Trading Days
9.03%
Link
LONG
Jan 3. 2019
3.40
Jan 4. 2019
3.65
1 Trading Days
7.21%
Link
Company Information
Stock Symbol
ASNS
Exchange
NASDAQ
Company URL
http://www.ascendispharma.com
Company Phone
45 36 94 44 86
CEO
Michael Wolff Jensen
Headquarters
-
Business Address
TUBORG BOULEVARD 5, HELLERUP, DENMARK DK-2900
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001612042
About

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies to address markets with unmet medical needs. The company was founded by Jan Møller Mikkelsen in September 2006 and is headquartered in Hellerup, Denmark.

Description

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Peptides for the treatment of diabetes; TransCon ranibizumab, a compound to support injection of ranibizumab in ophthalmology; TransCon parathyroid hormone for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It has strategic collaborations with Sanofi and Genentech. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.